58125
document
Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss diet . Increased arterial stiffness is associated with enhanced risk of cardiovascular disease in obese individuals . Whether n3 fatty acid ethyl ester ( FAEE ) supplementation improves arterial stiffness in obese participants on a weight loss diet has not yet been investigated . The objective of the study was to carry out a 12-wk randomized , single-blind trial to test the effect of a 25 % energy deficit weight loss diet alone ( WL ) ( n = 12 ) or WL plus 4 g/d Omacor ( 46 % EPA and 38 % DHA ) supplementation ( WL+FAEE ) ( n = 13 ) on arterial elasticity in obese adults . Large ( C1 ) and small artery elasticity ( C2 ) were measured by pulse contour analysis of the radial artery . WL alone reduced ( P < 0.05 in all ) body weight ( -3 % ) , waist circumference ( -4 % ) , systolic ( -3 % ) and diastolic ( -3 % ) blood pressures , cardiac output ( -4 % ) , plasma TG concentration ( -25 % ) , and the homeostasis model assessment ( HOMA ) score ( -12 % ) and increased plasma HDL cholesterol ( +9 % ) and adiponectin ( +18 % ) concentrations . However , WL alone did not alter C1 and C2 . The WL+FAEE intervention significantly reduced body weight ( -4 % ) , waist circumference ( -4 % ) , systolic ( -8 % ) and diastolic ( -5 % ) blood pressures , pulse pressure ( -5 % ) , heart rate ( -8 % ) , plasma TG concentration ( -36 % ) , and HOMA score ( -12 % ) and increased stroke volume ( +3 % ) , plasma HDL cholesterol ( +6 % ) and adiponectin concentrations ( +28 % ) , and C1 ( +20 % ) and C2 ( +22 % ) artery elasticity . The changes in systolic blood pressure , heart rate , plasma TGs , C1 , and C2 were significantly greater in the WL+FAEE group than in the WL group . Supplementation with n3 FAEEs improves C1 and C2 independently of weight loss in obese adults .
58126
Intervention_Pharmacological
n3 fatty acid ethyl esters
58127
Intervention_Pharmacological
n3 fatty acid ethyl ester ( FAEE ) supplementation
58128
Intervention_Other
energy deficit weight loss diet
58129
Intervention_Other
WL
58130
Intervention_Pharmacological
plus 4 g/d Omacor
58131
Intervention_Pharmacological
46 % EPA
58132
Intervention_Pharmacological
38 % DHA ) supplementation ( WL+FAEE )
58133
Intervention_Physical
WL
58134
Intervention_Pharmacological
WL+FAEE intervention
58135
Intervention_Pharmacological
WL+FAEE
58136
Intervention_Physical
WL
58137
Intervention_Pharmacological
n3 FAEEs
58138
Outcome_Physical
Large ( C1 ) and small artery elasticity ( C2 )
58139
Outcome_Physical
body weight
58140
Outcome_Physical
increased plasma HDL cholesterol
58141
Outcome_Physical
systolic
58142
Outcome_Physical
diastolic
58143
Outcome_Physical
pulse pressure
58144
Outcome_Physical
plasma TG concentration
58145
Outcome_Physical
increased stroke volume
58146
Outcome_Physical
systolic blood pressure
58147
Outcome_Physical
heart rate
58148
Outcome_Physical
plasma TGs
58149
Outcome_Physical
C1
58150
Outcome_Physical
C2
58151
Outcome_Physical
C1
58152
Outcome_Physical
C2
58153
Outcome_Physical
weight loss
58154
Participant_Condition
obese adults on a weight loss diet .
58155
Participant_Condition
weight loss diet alone ( WL ) ( n = 12 )
58156
Participant_Condition
obese adults .